Clinical use of Cyclosporine in Dermatology;Emprego Clínico da Ciclosporina em Dermatologia

Anais Brasileiros de Dermatologia

Volumn 76, Issue 4, 2001, Pages 361-378

  Zanini, Mauricio ^a   Camargo Neves, Samantha R ^a   Lacaz, Eduardo ^a   Paschoal, Luis Henrique Camargo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347710153     PISSN: 03650596     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (175)

1. Lim KK, Su WP, Schroeter AL, Sabers CJ, Abraham RT, Pittelkow MR. Cyclosporine in the treatment of dermatologic disease: an update. Mayo Clin Proc 1996; 71(12):1182-91.
2. Sowden JM, Allen BR. Cyclosporine in Dermatology: a historical overview. Int J Dermatol 1992; 31(7):520-3.
3. Borel JF, Feurer C, Gubler HU et al. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976;6: 468.
4. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45(6):953-1040.
5. June CH. T-cell proliferation involving the CD28 pathway is associated with cyclosporine resistant interleukin-2 gene expression. Mol Cell Biol 1987;7:4472.
6. Galvin F. Effects of cyclosporin A, FK506 and mycalamide A on the activation of murine CD4+ T-cells by the murine B7 antigen. Eur J Immunol 1993;23:283.
7. Fairley JA. Intracellular targets of cyclosporine. J Am Acad Dermatol 1990;23:1329.
8. Furue M, Gaspari AH, Katz SI. Effect of cyclosporin A on epidermal cells: cyclosporin A inhibits proliferation of normal and transformed keratinocytes. J Invest Dermatol 1988;90: 796-800.
9. Servitje O, Bordas X, Seron D et al. Changes in T-cell phenotype and adhesion molecules expression in psoriatic lesions after low-dose cyclosporin therapy. J Cutan Pathol 1996;23(5):431-6.
10. Prignano F, Domenici-Lombardo L, Gerlini G, Pimpinelli N, Romagnoli P. Cyclosporin A affects the organization of cytoskeleton of normal human keratinocytes in culture. Histol Histopathol 1996;11(4):889-94.
11. Dupuy P. Cyclosporin A innhibits the antigen-presenting functions of freshly isolated human Largerhans cells in vitro. J Invest Dermatol 1991;96:408.
12. Furst DE. Innovative treatment approaches for rheumatoid arthritis: cyclosporin, leflunomide and nitrogen mustard. Baillieres Clin Rheumatol 1995;9:711.
13. Noble S, Markham A. Cyclosporin: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs 1995;50:924.
14. Kovarik JM. Evidence of earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation 1996;62:759.
15. Somerville MF, Scott DGI. Neoral - New cyclosporin for old? Br J Rheumatol 1997;36:1113-15.
16. Watkins PB. The roles of cytochromes P-450 in cyclosporine metabolism. J Am Acad Dermatol 1990;23:1301.
17. Hoppu K. Comparison of conventional oral cyclosporine microemulsion formulation in children with a liver transplant. Transplantation 1996;62:66.
18. Mockli G. Laboratory monitoring of cyclosporine levels: guidelines for the dermatologist. J Am Acad Dermatol 1990;23:1275.
19. McFadden JP, Pontin JE, Powles AV et al. Cyclosporin decreases nifedipine metabolism. Br Med J 1989;299:1224.
20. Bos JD, Meinardi MMHM, van Joost T et al. Use of cyclosporin in psoriasis. Lancet 1989;2:1500-2.
21. Schofield OMV, Camp RDR, Levene GM. Cyclosporin A in psoriasis: interaction with carbamazepine. Br J Dermatol 1990; 122: 425-6.
22. Kovarik JM, Mueller EA, Gerbeau C, Tarral A, Francheteau P, Guerret M. Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potencial drug interactions and their implications for the treatment of rheumatoid arthritis. J Clin Pharmacol 1997;37(4):336-43.
23. Savin JA, Noble WC. Immunosuppression and skin infection. Br J Dermatol 1975;93:115-20.
24. Wolfson JS, Sober AJ, Rubin RH. Dermatologic manifestations of infection in the compromised host. Ann Rev Med 1983;34: 205-17.
25. Abel EA. Cutaneous manifestations of immunosuppression in organ transplant, recipients. J Am Acad Dermatol 1989;21: 167-79.
26. Bencini PL, Montagnino G, Sala F et al. Cutaneous lesions in 67 cyclosporin treated renal transplant recipients. Dermatologica 1986;172:24-30.
27. Rudlinger R, Smith IW, Bunney MH et al. Human papilloma infections in a group of renal transplant recipients. Br J Dermatol 1986;115:681-92.
28. Lutzner MA, Croissant O, Ducasse MF et al. A potentially oncogenic human papilloma virus (HPV-5) found in two renal allograft recipients. J Invest Dermatol 1988;75:353-6.
29. Daley TD, Wysocki GP, Day C. Clinical and pharmacological correlations in cyclosporin-induced gingival hyperplasia. Oral Surg 1986;62:417-21.
30. Slavin J, Taylor J. Cyclosporin, nifedipine and gingival hyperplasia. Lancet 1987;2:739.
31. Peterson JM, Barbul A, Breslin RJ. Significance of T lymphocytes in wound healing. Surgery 1987; 102:300-5.
32. Barbul A, Breslin RJ, Woodyard JP. The effect of in vivo T helper and T suppressor lymphocyte depletion on wound healing. Ann Surg 1989;209:479-83.
33. El-Shahawy MA, Gadallah MF, Massry Sg: Acne: a potencial side effect of cyclosporine A therapy. Nephron 1996;72(4):679-82.
34. Richter A, Beideck S, Bender W, Frosch PJ. Epidermal cysts and folliculitis caused by cyclosporin A. Hautarzt 1993;44(8):521-3.
35. Coffman TM. The thromboxane synthetase innibitor CGS 13080 improves renal allograft function in patients taking cyclosporine. Kidney Int 1990;37:604.
36. Perico N, Remuzz G. Cyclosporin-induced renal disfunction in experimental animals and humans. Transplant Ver 1991;5:63.
37. Bennett WM. Renal effects of cyclosporin. J Am Acad Dermatol 1990;23:1280.
38. Elzinga L, Kelley VE, Houghton DC et al. Modification of experimental nephrotoxicity with fish oil as the vehicle for cyclosporine. Transplantation 1987;43:271-5.
39. Chrysostomon A. Diltiazen in renal allograft recipients receiving cyclosporine. Transplantation 1993;55:330.
40. Pirsch JD. A controlled double-blind randomized trial of verapamil and cyclosporine cadaver renal transplant patients. Am J Kidney Dis 1993;21:189.
41. Anarat A, Noyan A. Gonlusen G, Duman N, Tuncer I. Influence of enalapril on experimental cyclosporin A nephrotoxicity. Abstract 1996;10(5):616-20.
42. Ates E, Sharma P, Erkasap S et al. Cyclosporine nephrotoxicity in the ischemic kidney and the protective effect of pentoxifylline: a study in the rat. Transplantation 1996;62(6):864-7.
43. Vanrenterghem Y. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985;1:999.
44. Grace AA. Cyclosporine A enhances platelet aggregation. Kidney Int 1987;32:889.
45. Ballantyne CM. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989;262:53.
46. Epstein A, Beall A, Wynn J, Mulloy L, Brophy CM. Cyclosporine, but not FK506, selectively induces renal and coronary artery smooth muscle contraction. Surgery 1998;123(4):456-60.
47. Braun-Dullaeus RC, Feussner M, Walker G et al. Cyclosporine-induced coronary artery constriction-dissociation between thromboxane release and coronary vasospam. J Heart Lung Transplant 1999;18(4):328-35.
48. Korstanje MJ, Van de Staak WJBM. High cumulative dose of ultraviolet radiation is a contraindication for cyclosporin therapy. Clin Exp Dermatol 1990;15:76.
49. Cockburn IT, Knipp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun 1989;2:723-31.
50. Catterall MD, Addis BJ, Smith JL et al. Sezary syndrome: transformation to a high grade T-cell lymphoma after treatment with cyclosporin A. Clin Exp Dermatol 1983;8:159-69.
51. Kageyama M, Fujita H, Nakata K, Shirasawa E, Kanai A. Effects of the immunosuppressant cyclosporin A on neurotransmitter release from peripheral non-adrenergic, non-cholinergic nerves. Abstract 1997;356(3):398-403.
52. Joss DV. Hypertension and convulsions in children receiving cyclosporin A. Lancet 1982;1:906.
53. Durrant S, Chipping PM, Palmer S, Gordon-Smith EC. Cyclosporin A, methylprednisolone and convulsions. Lancet 1982;2(8302):829-30.
54. Shuto H, Kataoka Y, Fujisaki K et al. Inhibition of GABA system involved in cyclosporine-induced convulsions. Life Sci 1999;65(9):879-87.
55. Gupta AK, Brown MD, Ellis CN et al. Cyclosporine in dermatology. J Am Acad Dermatol 1989;21:1245-56.
56. Harper JI, Kendra JR, Desai S et al. Dermatological aspects of the use of cyclosporin A for prophylaxis of gralt-versus-host disease. Br J Dermatol 1984;110: 469-74.
57. Epstein S. Organ transplantation and osteoporosis. Curr Opin Rheumatol 1995;7:255.
58. Lin HY. Cyclosporine-induced hyperuricemia and gout. N Engl J Med 1989;321:287.
59. Fernandez-Sola J. Reversible cyclosporin study myopathy. Lancet 1990;1:362.
60. Kahan BD. Cyclosporine: the ten year experience. Norwalk, Conn., Appleton and Lange, 1994.
61. Holland EJ, Chan C. Immunohistologic findings and results of treatment with cyclosporin in ligneous conjunctivitis. Am J Ophthalmol 1989;107:160-6.
62. Bos JD, Mevinharde MMHM, Van Joost T et al. Use of cyclosporin in psoriasis. Lancet 1989;2:1500-2
63. Zachariae H, Steen Olsen T. Efficacy of cyclosporin A in psoriasis: an overview of dose/response, indications, contraindications and side-effects. Clin Nephrol 1995;43:154.
64. Biren CA, Barr RJ. Dermatologic application of cyclosporine. Arch Dermatol 1986;122:1028-32.
65. Page EH, Wexler DM. Guenther LC. Cyclosporin A. J Am Acad Dermatol 1986;14:785-91.
66. Messana JM. Effects of cyclosporine on renal function in psoriasis patients. J Am Acad Dermatol 1990;23:1289.
67. Klintmalin GB. Cyclosporine A hepatotoxicity in 66 allograft recipients. Transplantation 1981;32:488.
68. Goldman EL. Study challenges mg/kg cyclosporine dosing. Skin All News 1998:29(7): 10.
69. Cilhar A, Pillar T, Ekzioni A. Topical cyclosporine in male pattern alopecia. J Am Acad Dermatol 1990;22:251-3.
70. Bousema MT, Tunk B, Heule F et al. Placebo-controlled study of psoriasis patients treated topically with a 10% cyclosporine gel. J Am Acad Dermatol 1990;22:126-7.
71. De Prost Y, Bodemer C, Teillac D. Randomised double-blind placebo-controlled trial of local cyclosporin in atopic dermatitis. Acta Derm Venereol 1989;144:136-8.
72. Eisen D, Griffiths CE, Ellis CN et al. Cyclosporin wash for oral lichen planus. Lancet 1990;335:535-6.
73. Hermann RC, Taylor RS, Ellis CN. Topical cyclosporin for psoriasis; in vitro skin penetration and clinical study. Skin Pharmacol 1988;1:246-9.
74. Petronic-Rosie VM. Marinkovic JM. Cvijetic OB. Intralesional cyclosporine versus dithranol in the treatment of plaque-type psoriasis. Eur J Dermatol 1997;7:492-6.
75. Ellis CN, Gorsulowski DC. Hamilton TA. Cyclosporine improves psoriasis in a double-blind study. J Am Med Assoc 1986;256:3110-16.
76. Van Joost T, Bos JD. Heule F et al. Low-dose cyclosporin A in severe psoriasis. A double-blind study. Br J Dermatol 1988;118:183-90.
77. Griffiths CEM, Powles AV, Leonard JN et al. Clearance of psoriasis with low dose cyclosporin. Br Med J 1986;293: 731-2.
78. Marks JM. Cyclosporin A treatment of severe psoriasis. Br J Dermatol 1986;115:745-6.
79. Meinardi MMHM, Westerhof W, Bos JD. Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. Br J Dermatol 1987;116:269-70.
80. Picascia DD, Garden JM, Freinkel RK et al. Treatment of resistant severe psoriasis with systemic cyclosporine. J Am Acad Dermatol 1987; 17: 408-14.
81. Van Hooff JP, Leunissen KML, Staak W. Cyclosporin and psoriasis. Lancet 1985;1:335.
82. Van Joost T, Heule F, Stolz E et al. Short-term use of cyclosporin A in severe psoriasis. Br J Dermatol 1986;114:615-20.
83. Wentzell JM, Baughman RD, O'Connor GT et al. Cyclosporin in the treatment of psoriasis. Arch Dermatol 1987;123:163-5.
84. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Eng J Med 1979;32:1017-25.
85. Meinardi MMHM, de Rie MA, Bos JD. Oral cyclosporin is effective in clearing persistent pustulosis palmaris et plantaris. Acta Derm Venereol 1990;70:77-9.
86. Reitamo S, Puska P, Lassus A. Cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol 1989;120:857.
87. Ruzicka T. Psoriatic arthritis:New types, new treatment. Arch Dermatol 1996;132:215.
88. Ellis CN. Cyclosporine for plaque-type psoriasis. N Engl J Med 1991;324:277.
89. Honeyman J, Sánchez L, Valdés P. Low-dose cyclosporine a improve severe disabling psoriasis in Latin America. Int J Dermatol 1995;34:583-8.
90. Meffert H, Bräuntigam M, Färber L, Weidinger G. Low-dose (1,25mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol 1997;77(2): 137-4.
91. Ozawa A, Sugai J, Ohkido M et al. Cyclosporin in psoriasis: continuos monotherapy versus intermittent long-term therapy. Eur J Dermatol 1999;9(3):218-23.
92. Sherry B. Intermittent cyclosporine effective for psoriasis. Skin Allergy News 1999;30(1):6.
93. Higgins E, Munro C, Marks J et al. Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A. Br J Dermatol 1989;121:71-4.
94. Gilhar A, Winterstein G, Golan DT. Topical cyclosporine in psoriasis. J Am Acad Dermatol 1988;18: 378-9.
95. Griffiths CEM, Powles AV, Baker BS et al. Topical cyclosporin and psoriasis. Lancet 1986;1:806.
96. Powles AV, Baker BS, McFadden J et al. Intralesional injection of cyclosporin in psoriasis. Lancet 1988;1:537.
97. Kokelj F, Torsello P, Plozzer C. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 1998;10(2):143-6.
98. Toyoda M. Norohashi M. Morphological assessment of the effects of cyclosporin A on mast cell-nerve relationship in atopic dermatitis. Acta Derm Venereol 1998;78(5):321-5.
99. Ross Js, Camp RDR. Cyclosporin A in atopic dermatitis. Br J Dermatol 1990;122 (Suppl.36): 41-5.
100. Motley RJ. Resolution of atopic dermatitis in a patient treated with cyclosporin. Clin Exp Dermatol 1989;14:243.
101. Taylor RS. Cyclosporine therapy for severe atopic dermatitis. J Am Acad Dermatol 1989;21:580.
102. Zonneveld IM. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. Br J Dermatol 1996;135(suppl 48): 15.
103. Berth-Jones J. Cyclosporin in severe childhood atopic dermatitis: A multicentre study. J Am Acad Dermatol 1996;34:1016.
104. Zaki I. Treatment of severe atopic dermatitis in childhood with cyclosporin Br J Dermatol 1996;135 (suppl 48):21.
105. Berth-Jones J, Graham-Brown RA, Marks R, Camp RD, et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997;136(1):76-81.
106. Zurbriggen B, Wüthrich B, Cachelin AB, Wili PB, Käggi MK. Camparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis: A double-blind, single-centre, cross-over pilot study. Dermatology 1999;198(1):56-60.
107. Ruzick T. A short-term trial of tacrolimus ointment for atopic dermatitis. European tacrolimus multicenter atopic dermatitis study group. N Engl J Med 1997;337:816.
108. Curley RK. Pyoderma gangrenosum treated with cyclosporin A. Br J Dermatol 1985;113:601.
109. Peter RU, Ruzicka T. Cyclosporin A in the therapy of inflammatory dermatoses. Hautarzt 1992;43:687.
110. Curley RK, Macfarlane AW, Vickers CFH. Pyoderma gangrenosum treated with cyclosporin A. Br J Dermatol 1985;113:601-4.
111. Theissen U. Erfolgreiche topische Anwendung von Cyclosporin A bei Pyoderma gangraenosum. Hautarzt 1996;47:132.
112. Theissen U, Luger TA, Schwarz T. Successful topical administration of cyclosporin A in pyoderma gangraenosum. Hautarzt 1996;47(2):132-5.
113. Pacor ML, Biasi D, Lunardi C, Cortina P, et al. Cyclosporin in Behçet's disease: results in 16 patients after 24 months of therapy. Clin Rheumatol 1994;13(2):224-7.
114. Sajjadi H, Soheilian M, Ahmadieh H, et al. Low dose cyclosporin A therapy in Behçet's disease. J Ocul Pharmacol 1994;10(3):553-60.
115. Masuda K, Nakajima A, Uravama A et al. Double masked study of cvclosporin versus colchicine, and long-term open study of cyclosporin in Behçet's disease. Lancet 1989;1:1094-6.
116. Muftuoglu A, Pazarli H, Yurdakul S et al. Short-term cyclosporin treatment of Behcet's disease. Br J Ophthalmol 1987;71:387-90.
117. Nussenblatt RB, Palestine AC. Cyclosporin: immunology, pharmacology and therapeutic uses. Survey Ophthalmol 1986;31:159-69.
118. Grattan CEH, Boon AP, Gregory J. A preliminary open study of topical cyclosporin for hypertrophic lichen planus. J Dermatol Treatment 1989;1:39-41.
119. Higgins EM, Munro CS, Friedmann PS et al. Cyclosporin A in the treatment of lichen planus. Arch Dermatol 1989;125:1436.
120. Ho VC, Gupta AK, Ellis CN et al. Treatment of severe lichen planus with cyclosporine. J Am Acad Dermatol 1990;22:64-8.
121. Patrone P, Stinco G, La Pia E, Frattasio A, De Francesco V. Surgery and cyclosporine A in the treatment of erosive lichen planus of the feet. Eur J Dermatol 1998;8(4):243-4.
122. Pigatto PD. Cyclosporin A for treatment of severe lichen planus. Br J Dermatol 1990;122:121.
123. Epstein JB, Truelove El. Topical cyclosporine in a bioadhesive for treatment of oral lichenoid mucosal reactions. An open label clinical trial. Oral Surg Oral Med 1996;82(5):532-6.
124. Morrison JGL, Schulz EJ. Treatment of eczema with cyclophosphamide and azathioprine. Br J Dermatol 1978;98:203-7.
125. Granlund H, Erkko P, Reitamo S. Comparison of the influence of cyclosporine and topical betamethasone-17,21-dipropionate treatment on quality of life in chronic hand eczema. Acta Derm Venereol 1997;77(1):54-8.
126. Granlund H, Erkko P, Reitamo S. Long-term follow-up of eczema patients treated with cyclosporine. Acta Derm Venereol 1998;78(1):40-3.
127. Zwillich T. Immunotherapy may benefit severe urticaria. Skin All News 1998;29(4):9.
128. Edström DW, Ros AM. Cyclosporin A therapy for severe solar urticaria. Phodermatol Photoimmunol Photomed 1997;13(1-2):61-3.
129. Toubi E, Blant A, Kessel A, Golan TD. Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 1997;52(3):312-6.
130. Klippel JH. Indications for, and use of, cytotoxic agents in SLE. Baillieres Clin Rheumatol 1998;12(3):511-27.
131. Caccavo D, Laganà B, Mitterhofer AP, Ferri GM et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 1997;40(1):27-35.
132. Graf N, Bambauer R, Jost W. The value of total plasma exchange and cyclosporin A in the treatment of systemic lupus erythematosus. Monatsschr Kinderheilkd 1999;138:395-8.
133. Heule F, van Joost T, Beukers R. Cyclosporine in the treatment of lupus erythematosus. Arch Dermatol 1986;122:973-4.
134. Makover D, Freundlich B, Zurier RB. Relapse of systemic lupus erythematosus in a patient receiving cyclosporine A. J Rheumatol 1988;15:117-19.
135. Alcocer-Varela A, Vidaller L, Llorente J et al. Presence of an IL-3 producing suppressor T-cell resistant to cyclosporin A in the peripheral blood of patients with systemic lupus erythematosus. Clin Exp Immunol 1988;73:424-9.
136. Casato M, Bonomo L, Caccavo D et al. Clinical effects of cyclosporin in dermatomyositis. Clin Exp Dermatol 1990;15:121-3.
137. Dantzig P. Juvenile dermatomyositis treated with cyclosporine. J Am Acad Dermatol 1990;2:310-11.
138. Pistoia V. Cyclosporine A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. Clin Exp Rheumatol 1993;11(2):203-8.
139. Drosos AA, Skopouli FN, Costopoulos JS et al. Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study. Ann Rheum Dis 1986;45:732-5.
140. Crow LL, Finkle JP, Gammon WR et al. Clearing of epidermolysis bullosa acquisita with cyclosporine. J Am Acad Dermatol 1988;19:937-42.
141. Crow LL. Clearing of epidermolysis bullosa acquisita on cyclosporin A. J Am Acad Dermatol 1988;19:937.
142. Connolly SM, Sander HM. Treatment of epidermolysis bullosa acquisita with cyclosporin. J Am Acad Dermatol 1987;16:890.
143. Barthelemy H, Biron F, Claudy A, et al. Cyclosporine: new immunosupressive agent in bullous penphigoid and pemphigus. Transplant Proc 1986;18:913-14.
144. Campolmi P, Bonan P, Lotti T et al. The role of cyclosporine A in the treatment of erythematosus pemphigus. Int J Dermatol 1991;30(12): 890-2.
145. Barthelemy H, Frappaz A, Cambazard F et al. Treatment of nine cases of pemphigus vulgaris with cyclosporin. J Am Acad Dermatol 1988;18:1262-6.
146. Gooptu C, Staughton RCD. Use of topical cyclosporin in oral pemphigus. J Am Acad Dermatol 1998;38:860-1.
147. Pacor ML, Biasi D, Carletto A, et al. Topical cyclosporin in the treatment of oral pemphigus. Minerva Stomatol 1998;47(4):183-6.
148. Correia SS, Boraso RZ, Júnior HTS. Almeida FA. Ciclosporina no tratamento do pênfigo vulgar. An bras Dermatol 1993;68(5):291-3.
149. Misciali C, Peluso AM, Cameli N et al. Occurrence of alopecia areata in a patient receiving systemic cyclosporine A. Arch Dermatol 1996;132(7):843-4.
150. Thein C, Strange P, Hansen ER. Lesional alopecia areata T lymphocytes downregulate epithelial cell proliferation. Arch Dermatol Res 1997;289(7):384-8.
151. Sawada M, Terada N, Taniguchi R et al. Cyclosporin A stimulates hair growth in nude mice. Lab Invest 1987;56:684-91.
152. Gilhar A, Pillar T, Etzioni A. The effect of topical cyclosporin on the immediate shedding of human scalp hair grafted onto nude mice. Br J Dermatol 1988;119:767-74.
153. Gupta AK, Ellis CN, Cooper KD et al. Oral cyclosporin for the treatment of alopecia areata. J Am Acad Dermatol 1990;22:242-8.
154. Cilhar A, Pillar T, Ekzioni A. Topical cyclosporin A in alopecia areata. Acta Derm Venereol 1989;69:252-3.
155. Maduit C, Leuvers P, Barthelmy H et al. Traitment des pelades sévères par application locales de cyclosporin A. Ann Dermatol Vénéréol 1987;114:507-10.
156. Shapiro J, Lui H, Tron V, Ho V. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic valuation. J Am Acad Dermatol 1997;36:114-7.
157. Paquet P, Pierard GE. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatol 1999;198(2):198-202.
158. ullivan JR, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin. A discussion of pathogenesis and immunosuppressive management. Australas J Dermatol 1996;37(4):208-12.
159. Moreland AA, Robertson DB, Heffner LT. Treatment of cutaneos T cell lymphoma and cyclosporin A. J Am Acad Dermatol 1985;12:886-7.
160. Harper JI, Kendra JR, Desai S et al. Dermatological aspects of the use of cyclosporin A for prophylaxis of graft-versus-host disease. Br J Dermatol 1984;110:469-74.
161. Powles RL, Clink HM, Spence D et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone marrow transplantation. Lancet 1980;1:327-9.
162. Vogelsang CB, Hess AD, Santos GW. Acute graft-versus-host disease: clinical characteristics in the cyclosporine era. Medicine 1988;67:163-74.
163. Wyser CP, van Schalkwyk B, Alheit PG, et al. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am Ver Respir Crit Care Med 1997;156:1371-76
164. York EL, Kovithavongs T, Man SF, et al. Cyclosporin and chronic sarcoidosis. Chest 1990;98(4):1026-9.
165. Mitruka SN, Pham SM, Zeevi A, et al. Aerosol cyclosporine prevents acute allografl rejection in experimental lung transplantation. J Thorac Cardiovasc Surg 1998;115(1):28-36.
166. Morris PG, Camp RDR, Hawk JLM. Actinic reticuloid. response to cyclosporin A. J Am Acad Dermatol 1989;21: 307-9.
167. Duschet P, Schwarz T, Oppolzer G et al. Persistent light reaction: successful treatment with cyclosporin. Acta Derm Venereol 1988;68:176-8.
168. Usuki K, Kitamura K, Urabe A. Succesful treatment of Weber-Christian disease with cyclosporin A. Am J Med 1988;85:276-8.
169. Komp D. The treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfmann Disease). Sem Diag Pathol 1990;7:83-6.
170. McLelland J, Pritchard J, Chu AC. Current controversies. Hematol Oncol Clin N Am 1987;1:147-62.
171. Broadbent V, Pritehard J, Yeoman E. Etoposide (VP16) in the treatment of multisystem Langerhans cell histiocytosis. Med Pediatr Oncol 1989;17:97-100.
172. Meyer P. Van Voorst PC. Lack of effect of cyclosporin A in pityriasis rubra pilaris. Acta Derm Venereol 1989;69: 272.
173. Dicken CH. Treatment of classicac pityriasis rubra pilar. J Am Acad Dermatol 1997;31(6):997-9.
174. Oxholm A, Homsen K, Menne T. Squamous cell carcinomas in relation to cyclosporin therapy of non-malignant skin disorders. Acta Derm Venereol 1988;69: 89-90.
175. Smith K. Ulceranting necrobiosis lipoidica resolving in response to cyclosporine A. Dermatol Online J 1997;3(1):2.